^
    Back
    Association details:
    Biomarker:ER positive
    Cancer:Endometrial Cancer
    Drug:Kisqali (ribociclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    09/20/2023
    Excerpt:
    Endometrial Carcinoma: SYSTEMIC THERAPY FOR ENDOMETRIAL CARCINOMA…Useful in Certain Circumstances…ER-positive tumors...Letrozole/ribociclib…
    Secondary therapy:
    letrozole
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer

    Excerpt:
    ...Tumors must stain positive for estrogen receptor (>= 10%) by immunohistochemistry (IHC)...
    Trial ID:
    NCT02657928
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ESMO Open
    Title:

    Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers

    Excerpt:
    Forty patients (20 OC and 20 EC) were enrolled. A PFS12 of 55% was observed in the EC cohort and 50% in the OC cohort. A PFS greater or equal to 24 weeks (PFS24) was seen in 20% (4/20) of the OC cohort and 35% (7/20) of the EC cohort….All three LGSOC patients obtained at least a partial response lasting for over 2 years, with two of the three patients still on treatment.
    Secondary therapy:
    letrozole
    DOI:
    10.1136/esmoopen-2020-000926.
    Trial ID:
    NCT02657928